An Open Label, First-in-human Study of BAY 2927088 in Participants With Advanced Non-small Cell Lung Cancer (NSCLC) Harboring an EGFR and/or HER2 Mutation
This study is testing a new medication called BAY 2927088 for people with advanced non-small cell lung cancer. It is designed to block specific proteins that cause cancer cells to grow and spread.
You may be eligible if you have advanced lung cancer that has a specific genetic mutation and has continued to grow after previous treatments. You must be able to provide a tumor sample and have tumors that can be clearly measured on medical scans.
Participants will take the medication as a pill or liquid once or twice daily in three-week cycles. You will visit the clinic regularly for check-ups, blood tests, and scans to monitor your health and how your tumor responds to the treatment.
This study is currently recruiting patients at various locations across the United States, including sites in Arizona, California, and Georgia.
- 1This study evaluates a new targeted therapy meant to stop cancer growth in patients with specific genetic markers.
- 2Participants will receive the study drug in cycles and undergo frequent health monitoring to ensure safety.
- 3The primary goal is to find the right dose of the medication and see how well it helps reduce or eliminate tumors.
No related links yet
Seen this study covered in the news, or found a page that explains it well? Send it over and we'll review it.
Suggest a linkThis summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.